Drugs / Raphamin
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07650227 | Dec 2025 → Dec 2028 expected | bronchitis | Materia Medica Holding | Recruiting | No outcome recorded |
| Phase 3 | NCT06901297 | Apr 2025 → Dec 2027 expected | sinusitis | Materia Medica Holding | Recruiting | No outcome recorded |
| Phase 3 | NCT06715891 | Nov 2024 → Dec 2027 expected | viral respiratory tract infection | Materia Medica Holding | Recruiting | No outcome recorded |
| Phase 3 | NCT06263881 | Dec 2023 → Mar 2025 | pneumonia | Materia Medica Holding | Completed | No outcome recorded |
| Phase 3 | NCT06284265 | Oct 2023 → Dec 2026 expected | chronic cystitis | Materia Medica Holding | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05364671 | Apr 2022 → Aug 2023 | COVID-19 | Materia Medica Holding | Completed | No outcome recorded |
| Phase 3 | NCT04918771 | Apr 2021 → Jul 2023 | viral respiratory tract infection | Materia Medica Holding | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Raphamin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04918771 ↗ |
| Route | Oral | “Oral administration - not with food.” NCT04918771 ↗ |